RxDoctor Payments DataLook up a doctor →

Jarod Williams, NP

Primary Care · Visalia, CANPI 1588156236

Payments from drug & device makers

$12,114in general payments, 2019–2025

Across 767 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$770
  • Amgen$602
  • Boehringer Ingelheim$584
  • Biohaven Pharmaceutical Holding Company Ltd.$442
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie87$1,621
Novo Nordisk171$1,419
Lilly USA, LLC63$770
Amgen33$602
Boehringer Ingelheim33$584
Biohaven Pharmaceutical Holding Company Ltd.36$442
Takeda Pharmaceuticals U.S.A., Inc.30$435
Mylan Specialty L.p.19$419
Pfizer28$393
AstraZeneca(2 entities)21$383
Corcept Therapeutics12$358
Bayer13$338
Otsuka America Pharmaceutical, Inc.14$286
Merck16$284
Biohaven Pharmaceuticals, Inc.19$280
Abiomed5$174
Xeris Pharmaceuticals, Inc.10$172
Lexicon Pharmaceuticals, Inc.4$167
Axsome Therapeutics, Inc.6$149
Amarin Pharma, Inc.13$144
Antares Pharma, Inc.6$140
Astellas Pharma US Inc7$136
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$127
GSK7$123
Therapeuticsmd, Inc.7$123
Ironwood Pharmaceuticals, Inc7$110
Agile Therapeutics, Inc.6$106
Phathom Pharmaceuticals, Inc.5$102
Lundbeck LLC4$102
Qiagen, LLC4$100
Organon6$92
Johnson & Johnson5$92
Idorsia Pharmaceuticals US Inc5$87
Viiv Healthcare Company1$85
Shield Therapeutics Inc4$84
Verity Pharmaceuticals Inc.4$76
Mayne Pharma Commercial LLC5$75
Abbott3$74
Daiichi Sankyo Inc.3$70
Dexcom, Inc.3$68
Vanda Pharmaceuticals Inc.3$56
Halozyme Inc2$53
Myovant Sciences Inc.3$52
Medtronic2$51
Hologic Sales And Service, LLC2$49
Viatris Specialty LLC2$43
Arbor Pharmaceuticals, Inc.2$36
Evofem Biosciences, Inc.2$35
Nalu Medical, Inc.1$32
Recordati_rare_diseases_inc.1$31
Novartis2$29
Tempus AI, Inc1$27
Nestle Healthcare Nutrition Inc.1$25
Coopersurgical, Inc.1$24
Optinose US, Inc.1$19
Genentech USA, Inc.1$19
Mimedx Group, Inc.1$18
Cranial Technologies, Inc1$18
Seqirus USA Inc1$17
Neurocrine Biosciences, Inc.1$17

How this compares

$12,114 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.

See all primary care providers in California

Medicare billing

Part B allowed, 2024
$226,989
Medicare patients
346
Services billed
4,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other primary care in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →